[1]Roberts SB, Wootton E, De Ferrari L, Albagha OM & Salter DME. pigenetics of osteoarticular diseases: recent developments. Rheumatology International. 2015;5:1293–1305. doi:10.1007/s00296–015–3260-y
[2] Bijlsma JW, Berenbaum F & Lafeber F P. Osteoarthritis: an update with relevance for clinical practice. Lancet. 2011;377:2115–2126. doi:10.1016/ S0140–6736(11)60243–2
[3]McAlindon TE, Bannuru RR, Sullivan MC, Arden NK, Berenbaum F, Bierma-Zeinstra SM, Hawker GA, Henrotin Y, Hunter DJ, Kawaguchi H. OARSI guidelines for the non-surgical management of knee osteoarthritis. Osteoarthritis and Cartilage. 2014;22:363–388. doi:10.1016/j.joca.2014.01.003
[4]Loeser RF, Goldring SR, Scanzello CR. & Goldring MB. Osteoarthritis: a disease of the joint as an organ. Arthritis and Rheumatism. 2012;64:1697–1707. doi:10.1002/art.34453
[5]Iozzo RV & Schaefer L. Proteoglycan form and function: a comprehensive nomenclature of proteoglycans. Matrix Biology. 2015;42:11–55. doi:10.1016/ j.matbio.2015.02.003
[6]Guo X, Ma W, Zhang F, Ren F, Qu C, Lammi MJ. Recent advances in the research of an endemic osteochondropathy in China: Kashin-Beck disease. Osteoarthritis and Cartilage. 2014;22:1774–1783. doi:10.1016/j.joca.2014.07.023
[7]Luo M, Chen J, Li S, Sun H, Zhang Z, Fu Q, Li J, Wang J, Hughes CE, Caterson B, Cao J. Changes in the metabolism of chondroitin sulfate glycosaminoglycans in articular cartilage from patients with Kashin-Beck disease. Osteoarthritis and Cartilage. 2014;22:986–995. doi:10.1016/j.joca.2014.05.012
[8]Li Y, Zhou Z, Shen B, Yang J, Kang P, Yang X, Liu G, Pei F. Clinical features of Kashin–Beck disease in adults younger than 50 years of age during a low incidence period: severe elbow and knee lesions. Clinical Rheumatology. 2013;32:317–324. doi:10.1007/s10067–012–2115–0
[9]Han J, Li D, Qu C, Wang D, Wang L, Guo X, Lammi MJ. Altered expression of chondroitin sulfate structure modifying sulfotransferases in the articular cartilage from adult osteoarthritis and Kashin-Beck disease. Osteoarthritis and Cartilage. 2017;25:1372–1375. doi:10.1016/j.joca.2017.02.803
[10]Han J, Wang W, Qu C, Liu R, Li W, Gao Z, Guo X. Role of inflammation in the process of clinical Kashin-Beck disease: latest findings and interpretations. Inflammation Research. 2015;64:853–860. doi:10.1007/s00011–015–0861–6
[11] Li S, Cao J, Caterson B & Hughes C E. Proteoglycan metabolism, cell death and Kashin-Beck disease. Glycoconjugate Journal. 2012;29:241–248. doi:10.1007/ s10719–012–9421–2
[12]Duan C, Guo X, Zhang XD, Yu HJ, Yan H, Gao Y, Ma MJ, Gao ZQ, Xu P, Lammi MJ. Comparative analysis of gene expression profiles between primary knee osteoarthritis and an osteoarthritis endemic to Northwestern China, Kashin-Beck disease. Arthritis Rheumatism. 2010;62:771–780. doi:10.1002/ art.27282
[13]Gualeni B, Facchini M, De Leonardis F, Tenni R, Cetta G, Viola M, Passi A, Superti-Furga A, Forlino A, Rossi A. Defective proteoglycan sulfation of the growth plate zones causes reduced chondrocyte proliferation via an altered Indian hedgehog signalling. Matrix Biology. 2010;29:453–460. doi:10.1016/ j.matbio.2010.05.001
[14] Vynios DH. Metabolism of cartilage proteoglycans in health and disease. BioMed Research International. 2014;2014:452315. doi:10.1155/2014/452315
[15]Responte DJ, Natoli RM & Athanasiou KA. Collagens of articular cartilage: structure, function, and importance in tissue engineering. Critical Reviews in Biomedical Engineering. 2007;35:363–411. doi:10.1615/CritRevBiomedEng. v35.i5.20
[16] Shaukat I. Investigation of the role of xylosyltransferases I and II and of the kinase Fam20B in the regulation of proteoglycan synthesis, Université de Lorraine. 2015
[17] Kiani C, Chen L, Wu y, Yee A & Yang BB. Structure and function of aggrecan. Cell Research. 2002;12:19–32. doi:10.1036/sj.cr.7290106
[18]Li L, Ly M & Linhardt RJ. Proteoglycan sequence. Molecular BioSystems. 2012;1613–1625. doi:10.1039/c2mb25021g.
[19] Koike T, Izumikawa T, Tamura JI & Kitagawa H. FAM20B is a kinase that phosphorylates xylose in the glycosaminoglycan-protein linkage region. Biochemical Journal. 2009;421:157–162. doi:10.1042/BJ20090474
[20] Koike T, Izumikawa T, Sato B & Kitagawa H. Identification of phosphatase that dephosphorylates xylose in the glycosaminoglycan-protein linkage region of proteoglycans. Journal of Biological Chemistry. 2014;289:6695–6708. doi:10.10 74/jbc.M113.520536
[21]Ma P, Yan W, Tian Y, Wang J, Feng J, Qin C, Cheng Y, Wang X. Inactivation of Fam20B in joint cartilage leads to chondrosarcoma and postnatal ossification defects. Scientific Reports. 2016; 6:29814. doi:10.1038/srep29814
[22]Nakajima M, Mizumoto S, Miyake N, Kogawa R, Iida A, Ito G, Kitoh H, Hirayama A, Mitsubuchi H, Miyazaki O. Mutations in B3GALT6, which encodes a glycosaminoglycan linker region enzyme, cause a spectrum of skeletal and connective tissue disorders. American Journal of Human Genetics. 2013;92:927–934. doi:10.1016/j.ajhg.2013.04.003
[23]Mikami T & Kitagawa H. Biosynthesis and function of chondroitin sulfate. Biochimica et Biophysica Acta. 2013;1830:4719–4733. doi:10.1016/ j.bbagen.2013.06.006
[24]China. Ministry of Health of the People’s Republic of China. Ministry of Health of the People’s Republic of China. Vol. WS/T207- 2010 (Beijing, 2010).
[25]Preedy VR & Watson RR. Western Ontario and McMaster universities osteoarthritis index. (Springer, 2010).
[26]Pritzker KP, Gay S, Jimenez SA, Ostergaard K, Pelletier JP, Revell PA, Salter D, van den Berg WB. Osteoarthritis cartilage histopathology: grading and staging. Osteoarthritis and Cartilage. 2006;14:13–29. doi:10.1016/j.joca.2005.07.014
[27]Ingavle GC, Frei AW, Gehrke SH & Detamore MS. Incorporation of aggrecan in interpenetrating network hydrogels to improve cellular performance for cartilage tissue engineering. Tissue Engineering. 2013;19:1349–1359. doi:10.1089/ ten.TEA.2012.0160
[28]Nia HT, Ortiz C, Grodzinsky A. Aggrecan: approaches to study biophysical and biomechanical properties. Methods in Molecular Biology. 2015;1229:221–237. doi:10.1007/978–1–4939–1714–3_20
[29]Morawski M, Brückner G, Arendt T & Matthews RT. Aggrecan: Beyond cartilage and into the brain. International Journal of Biochemistry and Cell Biology. 2012; 44:690–693. doi:10.1016/j.biocel.2012.01.010
[30]Stattin E, Wiklund F, Lindblom K, Onnerfjord P, Jonsson Bjornanders, Tegner Yelverton, Sasaki Takako, Struglics A, Lohmander Stefan, Dahl Niklas. A missense mutation in the aggrecan C-type lectin domain disrupts extracellular matrix interactions and causes dominant familial osteochondritis dissecans. American Journal of Human Genetics. 2010;86:126–137. doi:10.1016/ j.ajhg.2009.12.018
[31]Kitagawa H, Tsutsumi K, Ikegamikuzuhara A, Nadanaka S, Goto F, Ogawa T, Sugahara K. Sulfation of the galactose residues in the glycosaminoglycan-protein linkage region by recombinant human chondroitin 6-O-sulfotransferase–1. Journal of Biological Chemistry. 2008;283:27438–27443. doi:10.1074/ jbc.M803279200
[32]Wen J, Xiao J, Rahdar M, Choudhury B, Cui J, Taylor GS, Esko JD, Dixon JE. Xylose phosphorylation functions as a molecular switch to regulate proteoglycan biosynthesis. Proceedings of the National Academy of Sciences USA. 2014;111:15723–15728. doi:10.1073/pnas.1417993111
[33]Eames BF, Yan Y, Swartz ME, Levic DS, Knapik EW, Postlethwait JH, Kimmel. CBMutations in fam20b and xylt1 reveal that cartilage matrix controls timing of endochondral ossification by inhibiting chondrocyte maturation. PLoS Genetics. 2011;7:e1002246. doi:10.1371/journal.pgen.1002246
[34] Mizumoto S, Yamada S & Sugahara K. Mutations in biosynthetic enzymes for the protein linker region of chondroitin/dermatan/heparan sulfate cause skeletal and skin dysplasias. Biomedical Research International. 2015;2015:861752. doi:10.1155/2015/861752
[35]Katta K, Imran T, Busse-Wicher M, Gronning M, Czajkowski S, Kusche-Gullberg M. Reduced expression of EXTL2, a member of the exostosin (EXT) family of glycosyltransferases, in human embryonic kidney 293 cells results in longer heparan sulfate chains. Journal of Biological Chemistry. 2015;290:13168–13177. doi:10.1074/jbc.M114.631754
[36]Nadanaka S, Zhou S, Kagiyama S, Shoji N, Sugahara K, Sugihara K, Asano M, Kitagawa H. EXTL2, a member of the EXT family of tumor suppressors, controls glycosaminoglycan biosynthesis in a xylose kinase-dependent manner. Journal of Biological Chemistry. 2013;288:9321–9333. doi:10.1074/ jbc.M112.416909
[37]Nadanaka S & Kitagawa H. EXTL2 controls liver regeneration and aortic calcification through xylose kinase-dependent regulation of glycosaminoglycan biosynthesis. Matrix Biology. 2014;35:18–24. doi:10.1016/j.matbio.2013.10.010